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Abstract
Background: The Patient Determined Disease Steps (PDDS) is a promising patient-reported outcome (PRO) of
disability in multiple sclerosis (MS). To date, there is limited evidence regarding the validity of PDDS scores, despite
its sound conceptual development and broad inclusion in MS research. This study examined the validity of the
PDDS based on (1) the association with Expanded Disability Status Scale (EDSS) scores and (2) the pattern of
associations between PDDS and EDSS scores with Functional System (FS) scores as well as ambulatory and other
outcomes.
Methods: 96 persons with MS provided demographic/clinical information, completed the PDDS and other PROs
including the Multiple Sclerosis Walking Scale-12 (MSWS-12), and underwent a neurological examination for
generating FS and EDSS scores. Participants completed assessments of cognition, ambulation including the
6-minute walk (6 MW), and wore an accelerometer during waking hours over seven days.
Results: There was a strong correlation between EDSS and PDDS scores (ρ = .783). PDDS and EDSS scores were
strongly correlated with Pyramidal (ρ = .578 & ρ = .647, respectively) and Cerebellar (ρ = .501 & ρ = .528, respectively)
FS scores as well as 6 MW distance (ρ = .704 & ρ = .805, respectively), MSWS-12 scores (ρ = .801 & ρ = .729,
respectively), and accelerometer steps/day (ρ = −.740 & ρ = −.717, respectively).
Conclusion: This study provides novel evidence supporting the PDDS as valid PRO of disability in MS.
Background
The monitoring of disease progression among persons
with multiple sclerosis (MS) in clinical research and prac-
tice has typically been undertaken with the Kurtzke [1] Ex-
panded Disability Status Scale (EDSS) [2]. Based on its
shortcomings, researchers developed the Disease Steps
(DS) as a simple and reproducible assessment of disability
that can be undertaken by neurologists who are not spe-
cialists in MS [3,4]. The DS was developed based on
motor and ambulatory dysfunction representing the main
recognizable features of MS disability [3,4]. Researchers
initially reported a high concordance in ranking of sub-
jects between DS and EDSS scores (ρ = .958), and substan-
tial agreement in DS scores between raters (κ = .80) [3].
The same researchers later confirmed the high
concordance in rankings (ρ = .944), and reported correla-
tions between changes in DS and EDSS scores over 1
(ρ = .545), 2 (ρ = .635), and 3 (ρ = .626) year periods [4].
Other researchers further reported that the EDSS and DS
correlated similarly and reasonably with patient-reports of
neurological impairment, disability, and quality of life [5].
Researchers associated with the Patient Registry of
the North American Research Committee on MS
(NARCOMS) later developed the Patient Determined
Disease Steps (PDDS) scale as a patient-reported outcome
(PRO) of disability in MS [6]. The PDDS was adapted from
the physician administered DS [3,4] to be a surrogate of the
EDSS [7]. The PDDS has nine ordinal levels ranging be-
tween 0 (normal) and 8 (Bedridden) [8] and PDDS scores
can be converted into EDSS scores [9] as well as classifica-
tions of mild, moderate, or severe disability [10]. We do
recognise that the PDDS and EDSS scales are not
isomorphic, and there is not a direct correspondence be-
tween scores. Nevertheless, the PDDS scale has been
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included in research on spasticity [6], treatment patterns
[8], pain [11], fatigue [12], employment [13], comorbidities
[14,15], quality of life [16], and physical activity [17], for ex-
ample, in persons with MS.
To date, there has been limited research on the actual
validity of PDDS scores, despite its sound conceptual devel-
opment and inclusion in diverse studies of MS. We are
aware of only one study that reported a correlation between
PDDS and EDSS scores (ρ = .64) in 44 persons with MS
who had a median EDSS score of 3.5 [7]; that correlation is
not consistent with the often reported correlation coeffi-
cients of .93 [11] and .958 [9] for the validity of the PDDS.
The first correlation cannot be located for verification in
the frequently cited paper [5], whilst the second seemingly
represents the correlation between DS and EDSS scores [3].
Other researchers have reported associations between
PDDS scores and ambulation outcomes such as Multiple
Sclerosis Walking Scale-12 (MSWS-12) scores (ρ= .847),
six-minute walk (6 MW) performance (ρ = −.427), and free-
living accelerometry (ρ = .519) in 26 persons with MS [18];
this too provides limited evidence for the validity of the
PDDS, as this scale is heavily dependent upon ambulation
much like the DS and EDSS.
Overall, the PDDS is a promising PRO of disability that
is simple and economical compared with the EDSS and
DS and this scale has the potential to be used for the as-
sessment of disability in clinical practice and in clinical tri-
als. Yet, the current evidence for the validity of PDDS
scores is minimal and often misreported. To that end, this
study (1) examined the bivariate association between
PDDS and EDSS scores as an approach for providing evi-
dence of criterion validity for the PDDS and (2) compared
the bivariate associations between PDDS and EDSS scores
with Functional System (FS) scores, ambulatory outcomes,
cognitive processing speed, and clinical and demographic
factors in persons with MS as an approach for providing
evidence of convergent and divergent aspects of construct
validity for the PDDS.
Methods
Sample
The sample was recruited through neurology practices lo-
cated in the USA, and testing occurred in a single MS cen-
ter. The three inclusion criteria were (a) neurologist
confirmed diagnosis of MS [19] (b) capacity for independ-
ent ambulation or ambulation with an assistive device and
(c) willingness to voluntarily complete testing. Those who
had a relapse in the past 30 days were excluded from par-
ticipation. Participants were recruited through an email
flyer that was distributed among participants in a database
from previous studies conducted in the laboratory over the
past five years and through local media, promotional flyers
and medical records. Overall, 190 people were contacted,
124 were screened and recruited, but 28 cancelled and
were unable to be re-scheduled. The final sample included
96 patients who satisfied inclusion criteria and participated.
Measures
Timed 25-foot walk (T25FW)
The T25FW was administered as a measure of walking
speed. This assessment consisted of the participant walk-
ing 25 feet, with or without an assistive device, as quickly
and safely as possible in a hallway clear of obstacles. The
main outcome measure was the mean time (s) to complete
two trials of the T25FW [20]; shorter times reflect faster
walking speed.
Timed-Up-and-Go (TUG)
The TUG was administered as a measure of walking mo-
bility [21] as it involves standing up, walking, turning, and
sitting down. The TUG consisted of the participant sitting
on a chair, standing up with arms crossed over the chest,
walking around an object placed 10 feet in front of the
chair, and returning to a seated position on the chair as
quickly and safely as possible. The participants completed
two trials and the main outcome was mean time (s) to
complete the TUG [21] (i.e., time from arising from the
chair to the moment sitting back on the chair); shorter
times reflect better walking mobility.
Six-minute walk
The 6 MW was included as a measure of walking endur-
ance. The 6 MW was performed using a rectangular and
carpeted course with four hallways that each exceeded
50 m in length and that were clear of obstructions and foot
traffic. The participants walked around the entire course
during the 6 MW in a clockwise pattern. We provided
standardised instructions and emphasised walking as far
and as fast as possible for 6 minutes [22]. Distance was
recorded in meters (m) using a measuring wheel (Stanley
MW50, New Briton, CT); longer distances reflect better
walking endurance.
Multiple sclerosis walking scale-12
The MSWS-12 is a 12-item PRO of the impact of MS on
walking [23]. Example items are “In the past two weeks,
how much has MS limited your ability to walk?” and “In
the past two weeks, how much has MS slowed down your
walking?” The 12-items on the MSWS-12 are rated on a
scale ranging between 1 (Not at all) and 5 (Extremely).
The total MSWS-12 score is computed by summing the
individual item scores, subtracting the minimum possible
score (12), dividing by the maximal score (48), and then
multiplying the result by 100 [23]. The MSWS-12 score
ranges between 0 and 100; lower scores indicate less per-
ceived walking impairment.
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Abbreviated Late-Life Function and Disability Inventory
(LL-FDI)
The abbreviated LL-FDI is a multidimensional, PRO of
functional limitations and disability with psychometric evi-
dence of validity in persons with MS [24]. The functional
limitations component of the abbreviated LL-FDI was in-
cluded in this study and contains 15 items partitioned into
three, five-item subscales, namely advanced lower extremity
function (ALEF), basic lower extremity function (BLEF),
and upper extremity function (UEF). An example item for
the ALEF subscale was “How much difficulty do you have
with going up and down a flight of stairs outside, without
using a handrail?” An example item for the BLEF subscale
was “How much difficulty do you have using a step stool to
reach into a high cabinet?” An example item for the UEF
subscale was “How much difficulty do you have unscrewing
the lid off a previously unopened jar without using any
devices?”. The 15-items were rated on a 5-point ordinal
scale of 1 (none) and 5 (cannot do) and were reverse-
scored (i.e., 1 was re-coded into 5, whereas 5 was recorded
into 1) and then averaged to form composite measures of
ALEF, BLEF, and UEF. Scores for each five-item subscale
range between 5 and 25, and higher scores reflect fewer
functional limitations.
Free-living accelerometry
ActiGraph accelerometers (model GT3X; ActiGraph)
measure steps/day as an indication of free-living ambula-
tion in MS [25]. The ActiGraph accelerometers were worn
on a belt over the hip and measured steps using a solid
state digital accelerometer that generates an electrical signal
proportional to the force acting upon it during movement.
The steps were recorded over one-minute intervals, stored
in the accelerometer’s memory and later downloaded
using a personal computer. Steps per one-minute interval
were summed over the course of the day into steps/day.
Raw accelerometer data were checked against participant
recorded wear times from a log sheet and only valid days
(≥ 10 hours of wear time without periods of continuous
zeros exceeding 60 minutes) were included in the analysis.
The outcome of steps/day was averaged over 3 or more
available days of data, and higher scores reflect greater
community ambulation.
Cognitive processing speed
The 3-second Paced Auditory Serial Additional Test
(PASAT) and the Symbol Digit Modalities Test (SDMT)
were included as measures of cognitive processing speed.
These tests are relatively quick assessments and valid in
MS [26,27]. The PASAT emphasises auditory processing
speed and working memory, whereas the SDMT involves
visual/spatial processing speed and working memory; de-
tailed procedures for the PASAT and SDMT are provided
elsewhere [28]. The main outcome measure of the PASAT
was the total number of correct responses given out of a
possible 60 [26]. The main outcome measure of the
SDMT was the total number of correctly provided num-
bers (maximum of 110) in the 90 second period [27].
Higher scores on both assessments reflect faster cognitive
processing speed.
Procedure
The procedure was approved for human subjects research
by the University of Illinois College of Medicine at Peoria
Institutional Review Board and all participants provided
written informed consent. The data were collected from
each participant during one session in a single clinical set-
ting. There was no standardization of the exact ordering
of tests as more than one person underwent testing per
session. Rather, we varied the administration of tests such
that there was ample seated rest between the administra-
tion of walking outcomes (i.e., each walking outcome was
followed by a seated rest period and administration of a
non-ambulatory outcome as an approach for avoiding
motor fatigue). The participants provided demographic in-
formation, completed the PDDS, MSWS-12, and LL-FDI,
and underwent a neurological examination for generating
FS and Expanded Disability Status Scale (EDSS) scores [1].
This was accompanied by completion of the SDMT and
PASAT, T25FW, TUG, and 6 MW tests. The participants
were then provided with an accelerometer, belt, log, and
instructions for wearing the motion sensor during the
waking hours of the next seven days, along with a pre-
stamped and pre-addressed envelope for its return. All
participants received $20 remuneration upon return of the
motion sensor.
Validation framework
To establish criterion validity, the correlation between
PDDS and EDSS scores were examined as the EDSS is the
most common and accepted measure of disability status in
MS. To establish the convergent and divergent aspects of
construct validity, we examined the correlations between
PDDS scores with FS scores and other clinical outcomes.
The correlations with measures related to mobility (i.e.,
pyramidal functions, cerebellar functions, sensory func-
tions, 6 MW, T25FW, TUG, steps/day, BLEF and ALEF)
provided information on the convergent validity of the
PDDS, whilst comparisons with outcomes related to other,
non-mobility constructs (i.e. optic functions, brainstem
functions, bowel/bladder functions, mental status function,
demographic variables, UEF, SDMT and PASAT) provide
information on the divergent validity of the PDDS.
Data analysis
The data were analysed using IBM SPSS statistics version
19.0. Descriptive statistics were computed as median (range,
IQR), unless otherwise noted. The associations between
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variables were examined using Spearman rho rank-order
correlation coefficients (ρ) given that the EDSS and PDDS
are both ordered-categorical variables. This approach fur-
ther avoids the effects of outliers and non-normality on the
correlation coefficients [29]. Values for correlation coeffi-
cients of .1, .3, and .5 were interpreted as small, moderate,
and large, respectively [30]. We examined the significance
of differences in the magnitude of dependent correlations
between PDDS and EDSS scores with other variables [31];
the significance of differences was based on an alpha
value of .05.
Results
Demographic and clinical characteristics of sample
The demographic characteristics of the 96 patients with MS
are provided in Table 1. The sample had a median (IQR) age
of 53.5 (14) years and was mostly female (n = 77 or 80%).
The sample consisted of participants who were well edu-
cated (43% had a college education) and 59 percent earned
$40,000 or more annually. The sample consisted of mostly
individuals with relapsing remitting MS (82%) who had been
diagnosed for a median (IQR) duration of 9 (12) years.
Descriptive statistics for EDSS, PDDS, ambulatory,
functional, and cognitive outcomes
The descriptive characteristics of the variables are pro-
vided in Table 2. The median PDDS and EDSS scores were
3.0 and 4.5, respectively: the scores are indicative of mod-
erate disability with onset of gait impairment. The mean
scores from the other measures are consistent with previ-
ous research involving persons with MS who have moder-
ate disability [20-27].
Criterion validity: correlation between PDDS and EDSS
Overall, there was a strong correlation between EDSS and
PDDS scores (ρ = .783, 95% CI = .691-.850, p = .0001) and
the scatterplot of scores is provided in Figure 1. We fur-
ther regressed EDSS scores on PDDS scores (F (1,95) =
139.32, p < .001, R2 = .60), resulting in the regression
equation, EDSS score = 2.9 + .63 (PDDS score). This indi-
cates a strong linear association between scores, but that
scores between scales are not isomorphic, for example, as
a PDDS score of 0 corresponds with an EDSS score of 2.9.
The correlation between EDSS and PDDS scores remained
significant and strong within subsamples of mild (EDSS
<4.5, n = 37) and moderate-to-severe (EDSS ≥4.5, n = 59)
disability (mild: ρ = .641, 95% CI = .505-.746; moderate-to-
severe: ρ = .688, 95% CI = .566-.781).
Table 1 Demographic and clinical characteristics of the
96 multiple sclerosis patients
Variable Descriptive statistic
Age (yr) 53.5 (30–78, 14)
Sex (n, % female) 77, 80%
Education (n, % college education) 41, 43%
Income (n, % ≥ $40,000 year) 56, 59%
Race (n, % Caucasian) 91, 95%
MS Type (n, % RRMS) 79, 82%
Time since diagnosis (yr) 9 (1–43, 12)
Note. Values for age and disease duration are median (range, IQR). All other values
are N, percentage. MS =multiple sclerosis. RRMS = relapsing-remitting multiple
sclerosis. PDDS = Patient Determined Disease Steps scale; EDSS = Expanded Disability
Status Score.
Table 2 EDSS, PDDS, ambulatory, functional and
cognitive characteristics of the 96 patients with multiple
sclerosis
Variable Median (range, IQR)
EDSS 4.5 (2-6.5, 3.0)
PDDS 3.0 (0-6, 3.0)
T25FW (s) 6.0 (3.1-24.5, 3.6)
TUG (s) 8.0 (3.3-33.5, 5.3)
6 MW (m) 424.6 (59.6-773.6, 189.3)
MSWS-12 49.0 (0-93.8, 44.8)
LL-FDI (BLEF) 20.0 (8-25, 8.0)
LL-FDI (ALEF) 11.5 (5-25, 8.8)
LL-FDI (UEF) 20.0 (8-25, 7.0)
Accelerometry (steps/day) 3630 (419-13136, 3635)
PASAT 43.0 (0.0-60.0, 19.8)
SDMT 44.5 (15.0-79.0, 13.0)
Note. IQR = Inter Quartile Range , 6 MW – Six-minute Walk, T25FW – Timed-25
Foot Walk, TUG – Timed Up and Go, MSWS-12 – Multiple Sclerosis Walking Scale,
LLFDI – Late-Life Function and Disability Instrument, UEF – Upper Extremity
Function, BLEF – Basic Lower Extremity Function, ALEF – Advanced Lower
Extremity Function, SDMT – Symbol Digit Modalities Test, and PASAT – Paced
Auditory Serial Addition Test.
Figure 1 Scatterplot along with line of best fit and 95%
confidence intervals of Expand Disability Status Scale (EDSS)
and Patient Determined Disease Steps (PDDS) scores in 96
patients with multiple sclerosis.
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Construct Validity: correlations between PDDS and EDSS
with FS scores
The correlation coefficients and 95% confidence intervals
between PDDS and EDSS with FS scores from the EDSS
are provided in Table 3. Both PDDS and EDSS scores were
strongly correlated with Pyramidal and Cerebellar FS
scores, and moderately correlated with Sensory and Bowel/
Bladder FS scores. The correlations were generally small
between EDSS and PDDS with Visual, Mental, and Brain-
stem FS scores. Importantly, there were no significant
differences in the correlations between the EDSS and
PDDS scores with FS scores, based on the p-value from
Fisher’s z-test.
Construct validity: correlations between PDDS and EDSS
with demographic, ambulatory, functional, and cognitive
outcomes
The correlation coefficients for PDDS and EDSS with clin-
ical, demographic, ambulatory, function, and cognitive var-
iables are provided in Table 4. Both EDSS and PDDS
scores were strongly correlated with ambulatory assess-
ments (i.e., 6 MW, T25FW, TUG, Steps/day, & MSWS-12)
and assessments of basic and advanced lower extremity
functional (i.e., LL-FDI; BLEF & ALEF subscales). Both the
EDSS and the PDDS correlated moderately with age, upper
extremity function, and cognitive performance on SDMT.
EDSS and PDDS scores generally had small correlations
with MS disease duration, education, income, and cogni-
tive performance on PASAT. Importantly, there were no
significant differences in the correlations between the
EDSS and PDDS with clinical, demographic, ambulatory,
functional, and cognitive outcomes, based on the p-value
from Fisher’s z-test.
Discussion
The present study examined the association between PDDS
and EDSS scores and the associations between PDDS and
EDSS scores with FS scores, ambulatory outcomes, cogni-
tive processing speed, and clinical and demographic factors
in 96 persons with MS. Overall, the PDDS had a strong, al-
beit not perfect, correlation with the EDSS, supporting cri-
terion aspects of validity. The pattern and magnitude of
correlations with FS scores, ambulatory outcomes, cogni-
tive processing speed, and clinical and demographic vari-
ables further did not differ between the PDDS and EDSS,
and supported construct aspects of validity. The magnitude
and pattern of correlations between PDDS and EDSS scores
was consistent between persons with mild and moderate-to
-severe disability. Such results provide evidence for the
validity of PDDS scores as a PRO of disability in persons
with MS. The findings and limitations of this study do
not suggest that the PDDS should replace the EDSS in clin-
ical research, but rather that researchers and clinicians
might consider the PDDS as an alternative assessment
of disability, particularly when the EDSS is impractical (e.g.,
non-face-to-face research, lack of a clinician or other
trained personnel available for administration), too costly,
or inconvenient (e.g., time constraints of data collection,
community-based research). Such recommendations and
results are consistent with the original intention of the
PDDS serving as a surrogate measure for the EDSS in clin-
ical research involving MS.
This study examined the pattern of associations between
FS scores with both the EDSS and PDDS in a cross-
sectional analysis. Such an analysis is important for under-
standing the main components of neurological functioning
that correlate with PDDS scores, and if the pattern is con-
sistent between the PDDS and EDSS. The EDSS and
PDDS had strong correlations with Pyramidal and Cere-
bellar FS scores, and moderate correlations with Sensory
and Bowel/Bladder FS scores. The correlations were gen-
erally small between EDSS and PDDS with Visual, Mental,
and Brainstem FS scores. Importantly, there were no dif-
ferences in the magnitude of correlations between the
EDSS and PDDS scores with FS scores. This pattern of
correlations is generally consistent with previous research
examining the associations between FS and EDSS scores
in persons with MS [32,33] and suggests that motor
Table 3 Correlations among EDSS and PDDS with functional system scores from the EDSS in 96 patients with multiple
sclerosis
Functional system EDSS EDSS 95% CI PDDS PDDS 95% CI P-value
Visual 0.369** (0.182) - (0.530) 0.253* (0.055) – (0.432) .38
Brainstem 0.157 (−0.045) - (0.347) 0.184 (−0.017)- (0.371) .85
Pyramidal 0.647** (0.513) - (0.750) 0.578** (0.427) – (0.698) .45
Cerebellar 0.528** (0.366) - (0.659) 0.501** (0.334) – (0.637) .80
Sensory 0.398** (0.215) - (0.554) 0.392** (0.208) – (0.549) .96
Bladder/Bowel 0.317** (0.124) - (0.487) 0.377** (0.191) – (0.537) .64
Mental 0.255* (0.057) - (0.433) 0.169 (−0.033) – (0.357) .54
Note. EDSS = Expanded Disability Status Scale, PDDS = Patient Determined Disease Steps scale, P-value for the statistical significance of the difference between
correlation coefficients for EDSS and PDDS with FS scores, * = p < .05, ** = p < .01, CI = Confidence Interval.
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involvement is a primary contributor to PDDS and EDSS
scores. This supports the convergent aspects of construct
validity for the PDDS.
The present study further examined the association be-
tween PDDS scores and measures of ambulation as well as
demographic/clinical variables, cognition and functional
limitations. This was warranted as the PDDS was developed
based on the DS and this latter measure was primarily
designed based on ambulation and motor functioning being
the main determinants of disability in MS [3,4]. To that
end, analyses indicated that the PDDS was most strongly
correlated with ambulatory assessments (i.e., 6 MW,
T25FW, TUG, Steps/day, & MSWS-12) and assessments of
basic and advanced lower extremity functional limitations
(i.e., LL-FDI scores). Other researchers too have reported
associations between PDDS scores and MSWS-12 scores
(ρ= .847), 6 MW performance (ρ= −.427), and free-living
accelerometry (ρ= .519) in persons with MS [18]. Collect-
ively, such results along with the pattern of associations
with FS scores from the EDSS imply good convergent as-
pects of construct validity for the PDDS.
By comparison, the PDDS correlated moderately with
age, upper extremity functional limitations on the LL-
FDI, and performance on the SDMT, and weakly with
MS disease duration, education, income, and perform-
ance on the PASAT. Importantly, the EDSS and PDDS
correlated similarly with each of those outcomes. Such
evidence alongside the weaker correlations between
PDDS and EDSS with Visual, Mental, and Brainstem FS
scores supports the divergent aspects of construct
validity for the PDDS in persons with MS. Of further
interest herein is the moderate relationship between cog-
nitive processing speed (SDMT) and the EDSS and
PDDS. Future studies might consider examining if im-
pairment of cognitive processing speed influences the
validity of PDDS and EDSS scores.
The primary benefit of the evidence provided in the
current study is the provision of information on the
PDDS as a valid PRO of disability in persons with MS.
This is essential for building a stronger body of evidence
regarding the actual validity of PDDS scores and clarify-
ing misreporting of validity evidence in the literature.
Indeed, we identified a correlation of .783 (95% CI = .691-
.850) between PDDS and EDSS scores in the present
study, and this is substantially and significantly less than
the values of .93 and .958 often cited in the literature for
the validity of PDDS scale; we believe, as noted in the
introduction, that these large values may be unsubstanti-
ated or reflect the association between EDSS and DS. Our
correlation is stronger than the value of .64 reported in a
validation study of the Performance Scales, another self-
report of disability in MS [7]. Importantly, participants in
the earlier study [7] were less disabled (median EDSS = 3.5)
compared with the current sample (median EDSS = 4.5)
and this may have accounted for the difference in correla-
tions between studies. Indeed, analyses within disability
subgroups in the present study support this as a likely ex-
planation (i.e., the correlations were weaker, albeit still sig-
nificant and strong, in the subgroups who would have a
truncated range of scores). Overall, this study provides the
Table 4 Correlations among scores from the EDSS and PDDS with demographic, ambulatory, functional and cognitive
outcomes in 96 patients with multiple sclerosis
Variable category Measure EDSS EDSS 95% CI PDDS PDDS 95% CI P-value
Clinical/Demographic Disease duration 0.199* (−0.002) - (0.384) 0.202* (0.002) - (0.387) .98
Age 0.446** (0.270) - (0.593) 0.280** (0.084) - (0.455) .19
Education −0.352** (−0.516) - (−0.163) −0.274** (−0.450) - (−0.078) .56
Income −0.267** (−0.444) - (−0.070) −0.301** (−0.473) - (−0.107) .80
Ambulation 6 MW −0.805** (−0.866) - (−0.721) −0.704** (−0.793) - (−0.586) .11
T25FW 0.727** (0.616) - (0.809) 0.627** (0.488) - (0.735) .20
TUG 0.781** (0.688) - (0.849) 0.717** (0.603) - (0.802) .32
Accelerometry −0.717** (−0.802) - (−0.603) −0.740** (−0.819) - (−0.633) .74
MSWS-12 0.729** (0.619) - (0.811) 0.801** (0.715) - (0.863) .23
Function LL-FDI, BLEF −0.715** (−0.801) - (−0.601) −0.748** (−0.825)- (−0.644) .63
LL-FDI, ALEF −0.727** (−0.809) - (−0.616) −0.739** (−0.818) - (−0.632) .86
LL-FDI, UEF −0.392** (−0.549) - (−0.208) −0.445** (−0.593) -(−0.268) .66
Cognition SDMT −0.404** (−0.559) - (−0.221) −0.409** (−0.563) - (0.227) .97
PASAT −0.261* (−0.439) - (−0.064) −0.244* (−0.424) - (−0.046) .90
Note. EDSS = Expanded Disability Status Scale, PDDS = Patient Determined Disease Steps scale, P-value for the statistical significance of the difference between
correlation coefficients, 6 MW – Six-minute walk, T25FW – Timed-25 Foot Walk, TUG – Timed Up and Go, MSWS-12 – Multiple Sclerosis Walking Scale, LL-FDI –
Late-Life Function and Disability Instrument, BLEF – Basic Lower Extremity Function, ALEF – Advanced Lower Extremity Function, UEF – Upper Extremity Function,
SDMT – Symbol Digit Modalities Test, and PASAT – Paced Auditory Serial Addition Test, * = p < .05, ** = p < .01.
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first comprehensive assessment of the validity of PDDS
scores as a PRO of disability in persons with MS.
There are multiple limitations of the present study.
The first limitation is that we only provide validity evi-
dence from a cross-sectional analysis, rather than data
on the correspondence between changes in EDSS and
PDDS over time. It will be important to perform such a
longitudinal study, and doing so will allow for determin-
ation of the test-retest reliability of the PDDS over time.
Although persons with a wide range of disability were
included in this study, the results are limited in that our
sample did not cover the full disability range present in
persons with MS; there were no persons in the present
analysis with an EDSS score of less than 2. We further
did not include the DS in this study for an overall com-
parison of associations among EDSS, DS, and PDDS
scores together and with other outcomes. This would
have provided more definitive evidence on the source of
misreporting regarding the validity of PDDS scores. This
should be done as part of a longitudinal study. Lastly,
the sample consisted mostly of Caucasian women with
RRMS and a short disease-duration, and our results
might not be generalizable broadly amongst those with
MS. We only examined the validity of an English, print
version of the PDDS, and future research should validate
the PDDS in different languages and cultures as well as
using electronic media (e.g. applications on cellular
phones, the Internet, or tablets in the office or at home).
Conclusions
Overall, this study provides novel and comprehensive in-
formation supporting the validity of the PDDS as a PRO
of disability in persons with MS. The PDDS is an alterna-
tive to other, more complex, self-reported versions of the
EDSS that have correlated well with the classical EDSS
[34], but that still require significant amounts of time
and have items that can be confusing for participants.
Researchers could adopt the PDDS in clinical research
and practice involving persons with MS alongside the
EDSS or when the EDSS is impractical, too costly, or in-
convenient. The PDDS scale is simple, economical, and ef-
ficient compared with the EDSS and DS and offers a
potentially useful PRO of disability for clinical research
and practice in MS.
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